These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 21392016)

  • 1. FDA workshop on emerging infectious diseases: evaluating emerging infectious diseases (EIDs) for transfusion safety.
    Atreya C; Nakhasi H; Mied P; Epstein J; Hughes J; Gwinn M; Kleinman S; Dodd R; Stramer S; Walderhaug M; Ganz P; Goodrich R; Tibbetts C; Asher D
    Transfusion; 2011 Aug; 51(8):1855-71. PubMed ID: 21392016
    [No Abstract]   [Full Text] [Related]  

  • 2. Advancing risk assessment for emerging infectious diseases for blood and blood products: proceedings of a public workshop.
    Gallagher LM; Ganz PR; Yang H; Kessler DA; O'Brien SF; Custer BS; Busch MP; Dodd RY; Stramer SL; Walderhaug MO; Forshee RA; Williams AE; Epstein JS; Anderson SA
    Transfusion; 2013 Feb; 53(2):455-63. PubMed ID: 22845334
    [No Abstract]   [Full Text] [Related]  

  • 3. Insight into "Calculated Risk": An Application to the Prioritization of Emerging Infectious Diseases for Blood Transfusion Safety.
    Neslo REJ; Oei W; Janssen MP
    Risk Anal; 2017 Sep; 37(9):1783-1795. PubMed ID: 28229466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging infectious agents and the nation's blood supply: responding to potential threats in the 21st century.
    Glynn SA; Busch MP; Dodd RY; Katz LM; Stramer SL; Klein HG; Simmons G; Kleinman SH; Shurin SB;
    Transfusion; 2013 Feb; 53(2):438-54. PubMed ID: 22690676
    [No Abstract]   [Full Text] [Related]  

  • 5. First "themed issue" of Transfusion on thirty years of progress in blood safety since recognition of transfusion-associated AIDS.
    Busch MP; Ness PM
    Transfusion; 2013 Oct; 53(10 Pt 2):2357-8. PubMed ID: 24099405
    [No Abstract]   [Full Text] [Related]  

  • 6. Babesia: an emerging infectious threat in transfusion medicine.
    Lobo CA; Cursino-Santos JR; Alhassan A; Rodrigues M
    PLoS Pathog; 2013; 9(7):e1003387. PubMed ID: 23853577
    [No Abstract]   [Full Text] [Related]  

  • 7. The Impact of Emerging Infectious Diseases on Chinese Blood Safety.
    He M; Wang J; Chen L; Liu J; Zeng P
    Transfus Med Rev; 2017 Apr; 31(2):94-101. PubMed ID: 27923518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging Infectious Diseases and Blood Safety: Modeling the Transfusion-Transmission Risk.
    Kiely P; Gambhir M; Cheng AC; McQuilten ZK; Seed CR; Wood EM
    Transfus Med Rev; 2017 Jul; 31(3):154-164. PubMed ID: 28545882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ten years of nucleic acid testing: lessons and prospects].
    Morel P
    Transfus Clin Biol; 2011 Apr; 18(2):133-9. PubMed ID: 21397544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and emerging infectious risks of blood transfusions.
    Busch MP; Kleinman SH; Nemo GJ
    JAMA; 2003 Feb; 289(8):959-62. PubMed ID: 12597733
    [No Abstract]   [Full Text] [Related]  

  • 11. Reflections on the emergence of chikungunya virus in the United States: time to revisit a successful paradigm for the safety of blood-derived therapies.
    Farrugia A; Kreil TR
    Transfusion; 2015 Jan; 55(1):224-6. PubMed ID: 25582241
    [No Abstract]   [Full Text] [Related]  

  • 12. The potential threat to blood transfusion safety of emerging infectious disease agents.
    Stramer SL
    Clin Adv Hematol Oncol; 2015 Jul; 13(7):420-2. PubMed ID: 26353036
    [No Abstract]   [Full Text] [Related]  

  • 13. [Assessment of a transfusion emergent risk: the case of HEV].
    Pillonel J; Gallian P; Sommen C; Couturier E; Piquet Y; Djoudi R; Laperche S;
    Transfus Clin Biol; 2014 Nov; 21(4-5):162-6. PubMed ID: 25267205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A consensus-based tool for ranking the risk of blood-transmissible infections.
    Oei W; Neslo R; Janssen MP
    Transfusion; 2016 Aug; 56(8):2108-14. PubMed ID: 27217225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Blood transfusion and infectious diseases].
    Hamaguchi I
    Rinsho Byori; 2013 May; 61(5):414-7. PubMed ID: 23947180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transfusion safety: Where are we today?
    Luban NL
    Ann N Y Acad Sci; 2005; 1054():325-41. PubMed ID: 16339681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International travel and blood donation: risks and restrictions.
    Flaherty G; Moran B; Higgins P
    J Travel Med; 2017 May; 24(3):. PubMed ID: 28881861
    [No Abstract]   [Full Text] [Related]  

  • 18. Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026).
    Atreya C; Glynn S; Busch M; Kleinman S; Snyder E; Rutter S; AuBuchon J; Flegel W; Reeve D; Devine D; Cohn C; Custer B; Goodrich R; Benjamin RJ; Razatos A; Cancelas J; Wagner S; Maclean M; Gelderman M; Cap A; Ness P
    Transfusion; 2019 Sep; 59(9):3002-3025. PubMed ID: 31144334
    [No Abstract]   [Full Text] [Related]  

  • 19. Zika Virus and Patient Blood Management.
    Goodnough LT; Marques MB
    Anesth Analg; 2017 Jan; 124(1):282-289. PubMed ID: 27902502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Universal implementation of pathogen inactivation in labile blood products is a major step towards transfusion safety].
    Cazenave JP
    Bull Acad Natl Med; 2010 Dec; 194(9):1707-19; discussion 1719-20. PubMed ID: 22043595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.